DE602005018222D1 - - Google Patents

Info

Publication number
DE602005018222D1
DE602005018222D1 DE602005018222T DE602005018222T DE602005018222D1 DE 602005018222 D1 DE602005018222 D1 DE 602005018222D1 DE 602005018222 T DE602005018222 T DE 602005018222T DE 602005018222 T DE602005018222 T DE 602005018222T DE 602005018222 D1 DE602005018222 D1 DE 602005018222D1
Authority
DE
Germany
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005018222T
Other languages
German (de)
Inventor
Hiroyasu Yasuda
Mutsuo Yamaya
Katsutoshi Nakayama
Hidetada Sasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Publication of DE602005018222D1 publication Critical patent/DE602005018222D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE602005018222T 2004-06-10 2005-06-10 Expired - Lifetime DE602005018222D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004173174 2004-06-10
PCT/JP2005/011078 WO2005120493A1 (en) 2004-06-10 2005-06-10 Anticancer effect enhancer

Publications (1)

Publication Number Publication Date
DE602005018222D1 true DE602005018222D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-01-21

Family

ID=34970391

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005018222T Expired - Lifetime DE602005018222D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2004-06-10 2005-06-10

Country Status (8)

Country Link
US (2) US20080039521A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1778215B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP4729503B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20070045187A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN101001623B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE602005018222D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2338022T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2005120493A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
JP2010024170A (ja) * 2008-07-17 2010-02-04 Hiroshi Maeda 抗悪性腫瘍剤の腫瘍組織への局所送達増強剤
WO2010044875A2 (en) * 2008-10-16 2010-04-22 Novan, Inc. Nitric oxide releasing particles for oral care applications
US20100111857A1 (en) * 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8603496B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9072799B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9056047B2 (en) 2008-10-31 2015-06-16 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8485861B2 (en) * 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8603495B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US20100111845A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731840B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8721583B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111834A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111831A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US9050070B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8725420B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8793075B2 (en) * 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731841B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111836A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060934B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US20100111835A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) * 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8784385B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen piercing implements and methods for piercing a substrate
US8603494B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
CN102695528B (zh) 2009-08-21 2016-07-13 诺万公司 创伤敷料、其使用方法及其形成方法
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
US20110086234A1 (en) * 2009-10-13 2011-04-14 Nathan Stasko Nitric oxide-releasing coatings
CN102107009A (zh) * 2009-12-25 2011-06-29 奇复康药物研发(苏州)有限公司 天然药物组分和一氧化氮供体的混合复方药物及其用途
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
JP5842367B2 (ja) * 2011-04-07 2016-01-13 ニプロ株式会社 抗癌剤増感剤
US20140088034A1 (en) * 2011-05-11 2014-03-27 Stc.Unm NITRIC OXIDE/cGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION
CN103130815B (zh) * 2013-02-07 2015-10-07 浙江工业大学 一种单硝酸异山梨酯衍生物及其制备方法和应用
WO2015125934A1 (ja) 2014-02-20 2015-08-27 国立大学法人大阪大学 抗癌剤の抗腫瘍効果の増強剤
US10214743B2 (en) 2014-03-04 2019-02-26 Hirofumi Yamamoto Colorectal cancer drug, and method for predicting prognosis of colorectal cancer patient
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
CN107823644B (zh) * 2017-11-07 2021-03-02 福州大学 一种no供体化合物在制备抑制富含巯基分子的肿瘤细胞的侵袭和转移能力药物中的应用
CN109498818B (zh) * 2018-05-25 2021-08-31 福州大学 一种产生NO的pH敏感脂质体及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0722320B1 (en) * 1993-10-08 2000-07-19 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Use of nitric oxide-releasing compounds as medicaments for hypoxic cell radiation sensitization
EP0888458A4 (en) * 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
IT1282686B1 (it) * 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
EP1251840A2 (en) 2000-01-26 2002-10-30 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
TWI293878B (en) * 2000-06-30 2008-03-01 Taipei Veterans General Hospital A composition comprising a mevalonate-reducing compound for sensitizing cancer cells to cancer therapies and kits comprising said composition and an anti-cancer agent
AU2003208228A1 (en) * 2002-03-06 2003-09-16 Cellegy Pharmaceuticals, Inc Formulations and methods of using nitric oxide mimetics in cancer treatment

Also Published As

Publication number Publication date
US8410175B2 (en) 2013-04-02
EP1778215A1 (en) 2007-05-02
US20080039521A1 (en) 2008-02-14
EP1778215B1 (en) 2009-12-09
JP2011144190A (ja) 2011-07-28
ES2338022T3 (es) 2010-05-03
WO2005120493A1 (en) 2005-12-22
JP4729503B2 (ja) 2011-07-20
KR20070045187A (ko) 2007-05-02
WO2005120493A8 (en) 2007-03-22
CN101001623A (zh) 2007-07-18
CN101001623B (zh) 2010-11-17
JP2008501630A (ja) 2008-01-24
US20090137683A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
BE2024C508I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2023C542I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2021C001I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2020C513I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2020C517I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C540I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C523I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C548I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C506I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2018C045I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2020C525I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C063I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C027I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C023I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C002I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C067I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C041I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C038I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C015I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2014C071I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2014C064I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2014C063I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition